Perspective Therapeutics, Inc. (CATX)

NYSEAMERICAN: CATX · IEX Real-Time Price · USD
0.915
+0.037 (4.26%)
Feb 20, 2024, 4:00 PM EST - Market closed
4.26%
Market Cap 451.43M
Revenue (ttm) 8.17M
Net Income (ttm) -25.10M
Shares Out 493.31M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,574,785
Open 0.882
Previous Close 0.878
Day's Range 0.860 - 0.925
52-Week Range 0.210 - 1.000
Beta 1.51
Analysts Strong Buy
Price Target 1.27 (+38.78%)
Earnings Date Mar 5, 2024

About CATX

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isor... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1983
Employees 91
Stock Exchange NYSEAMERICAN
Ticker Symbol CATX
Full Company Profile

Financial Performance

In 2022, CATX's revenue was $10.80 million, an increase of 7.38% compared to the previous year's $10.05 million. Losses were -$7.27 million, 114.5% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price forecast is $1.27, which is an increase of 38.78% from the latest price.

Price Target
$1.27
(38.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

SEATTLE, Feb. 01, 2024 (GLOBE NEWSWIRE) --  -- Perspective Therapeutics, Inc.  (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatme...

19 days ago - GlobeNewsWire

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

4 weeks ago - GlobeNewsWire

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a...

4 weeks ago - GlobeNewsWire

Perspective Therapeutics Announces Proposed Public Offering

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap...

4 weeks ago - GlobeNewsWire

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical ...

4 weeks ago - GlobeNewsWire

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) --   Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced it entered into strategic agreements with Lantheus Holdings, Inc., the leading radiop...

6 weeks ago - GlobeNewsWire

Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company's Chief Executive Office...

7 weeks ago - GlobeNewsWire

Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors

SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of...

2 months ago - GlobeNewsWire

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided re...

3 months ago - GlobeNewsWire

Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma

SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient co...

4 months ago - GlobeNewsWire

Perspective Therapeutics' Cesium-131 Featured at the American Society for Radiation Oncology's Annual Conference

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and c...

4 months ago - GlobeNewsWire

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective T h erapeutics, Inc.  (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two pr...

6 months ago - GlobeNewsWire

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) --   Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at...

6 months ago - GlobeNewsWire

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

RICHLAND, Wash. and CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing ...

6 months ago - GlobeNewsWire

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alp...

6 months ago - GlobeNewsWire

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

RICHLAND, WASHINGTON & CORALVILLE, IOWA , June 21, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developi...

8 months ago - GlobeNewsWire

Perspective Therapeutics' Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society's Annual Meeting

Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the meeting Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in...

8 months ago - GlobeNewsWire

Perspective Therapeutics to Present at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS)

Three poster presentations from Perspective Therapeutics' scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, 2 03Pb m...

9 months ago - GlobeNewsWire

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and com...

10 months ago - GlobeNewsWire

Perspective Therapeutics Announces Changes to the Board of Directors

RICHLAND, WA & CORALVILLE, IA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary...

10 months ago - GlobeNewsWire

Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care

BOCA RATON, Fla. and RICHLAND, Wash., March 14, 2023 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and manufacturing organization and radiopharmac...

1 year ago - PRNewsWire